The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
Open accessAbstract
Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological type of esophageal cancer, predominantly constituting 90% of cases worldwide. Despite the development of multidisciplinary therapeutic approaches, its prognosis remains unfavorable. Recently, the development of monoclonal antibodies inhibiting programmed death 1 (PD‐1) or programmed death‐ligand 1 (PD‐L1) has led to marked therapeutic responses among multiple malignancies including ESCC. However, only a few patients achieved clinical benefits due to resistance. Therefore, precise and accurate predictive biomarkers should be identified for personalized immunotherapy in clinical settings. Because the tumor immune microenvironment can potentially influence the patient's response to immune checkpoint inhibitors, tumor immunity, such as PD‐L1 expression on tumors, tumor‐infiltrating lymphocytes, tumor‐associated macrophages, and myeloid‐derived suppressor cells, in ESCC should be further investigated. In this review, accumulated evidence regarding the tumor immune microenvironment and immune checkpoint inhibitors in ESCC are summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Nomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2706 · Cited by 1,518
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Rustgi, A. K., & El-Serag, H. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314530 · Cited by 1,243
Kato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C.-Y., Chin, K., Kadowaki, S., Ahn, M.-J., Hamamoto, Y., Doki, Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30626-6 · Cited by 1,213
Kojima, T., Shah, M. A., Muro, K., Francois, E., Adenis, A., Hsu, C.-H., Doi, T., Moriwaki, T., Kim, S.-B., Lee, S.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01888 · Cited by 1,126
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2477 · Cited by 665
Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6212 · Cited by 624
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., & Middleton, G. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 575
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Schumacher, K., Haensch, W., Röefzaad, C., & Schlag, P. M. (2001) · PubMed · Cited by 503
Nosho, K., Baba, Y., Tanaka, N., Shima, K., Hayashi, M., Meyerhardt, J. A., Giovannucci, E., Dranoff, G., Fuchs, C. S., & Ogino, S. (2010) · The Journal of Pathology · doi:10.1002/path.2774 · Cited by 502
Self-citationShah, M. A., Kojima, T., Hochhauser, D., Enzinger, P., Raimbourg, J., Hollebecque, A., Lordick, F., Kim, S.-B., Tajika, M., Kim, H. T., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5441 · Cited by 496
Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30181-x · Cited by 377
Doi, T., Piha-Paul, S. A., Jalal, S. I., Saraf, S., Lunceford, J., Koshiji, M., & Bennouna, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9846 · Cited by 318
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 271
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Komohara, Y., Hasita, H., Ohnishi, K., Fujiwara, Y., Suzu, S., Eto, M., & Takeya, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01945.x · Cited by 264
Cohen, R., Hain, E., Buhard, O., Guilloux, A., Bardier, A., Kaci, R., Bertheau, P., Renaud, F., Bibeau, F., Fléjou, J.-F., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4942 · Cited by 248
Kojima, T., Muro, K., Francois, E., Hsu, C.-H., Moriwaki, T., Kim, S.-B., Lee, S.-H., Bennouna, J., Kato, K., Lin, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.2 · Cited by 202
Shigeoka, M., Urakawa, N., Nakamura, T., Nishio, M., Watajima, T., Kuroda, D., Komori, T., Kakeji, Y., Semba, S., & Yokozaki, H. (2013) · Cancer Science · doi:10.1111/cas.12188 · Cited by 183
Yagi, T., Baba, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., & Baba, H. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002616 · Cited by 182
Self-citationKato, K., Shah, M. A., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., Sun, J.-M., Cho, B. C., Özgüroğlu, M., Kojima, T., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0609 · Cited by 171
Karakasheva, T. A., Waldron, T. J., Eruslanov, E., Kim, S.-B., Lee, J.-S., O'Brien, S., Hicks, P. D., Basu, D., Singhal, S., Malavasi, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3639 · Cited by 166
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 164
Chen, M., Kuan, F., Yen, T., Lu, M., Lin, P.-Y., Chung, Y.-H., Chen, W., & Lee, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2368 · Cited by 158
Precision immunoprofiling by image analysis and artificial intelligence
Koelzer, V. H., Sirinukunwattana, K., Rittscher, J., & Mertz, K. D. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2485-z · Cited by 151
Wolchok, J. D. (2015) · Cell · doi:10.1016/j.cell.2015.07.045 · Cited by 139
Yagi, T., Baba, Y., Okadome, K., Kiyozumi, Y., Hiyoshi, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.018 · Cited by 116
Self-citationMiyasato, Y., Shiota, T., Ohnishi, K., Pan, C., Yano, H., Horlad, H., Yamamoto, Y., Yamamoto‐Ibusuki, M., Iwase, H., Takeya, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13287 · Cited by 111
Chen, K., Cheng, G., Zhang, F., Zhang, N., Li, D., Jin, J., Wu, J., Ying, L., Mao, W., & Su, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8956 · Cited by 110
Greally, M., Chou, J. F., Chatila, W. K., Margolis, M. L., Capanu, M., Hechtman, J. F., Tuvy, Y., Kundra, R., Daian, F., Ladanyi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3603 · Cited by 104
Somaiah, N., Block, M. S., Kim, J. W., Shapiro, G. I., Do, K. T., Hwu, P., Eder, J. P., Jones, R. L., Lu, H., ter Meulen, J. H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1025 · Cited by 87
Harnessing NK Cells for Cancer Treatment
Minetto, P., Guolo, F., Pesce, S., Greppi, M., Obino, V., Ferretti, E., Sivori, S., Genova, C., Lemoli, R., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02836 · Cited by 81
Porta, C., Sica, A., & Riboldi, E. (2017) · FEBS Journal · doi:10.1111/febs.14288 · Cited by 72
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
Okadome, K., Baba, Y., Nomoto, D., Yagi, T., Kalikawe, R., Harada, K., Hiyoshi, Y., Nagai, Y., Ishimoto, T., Iwatsuki, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0811-0 · Cited by 65
Self-citationPrognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis
Zheng, X. W., Song, X., Shao, Y., Xu, B., Hu, W., Zhou, Q., Chen, L., Zhang, D., Wu, C., & Jiang, J. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487164 · Cited by 64
Ito, S., Okano, S., Morita, M., Saeki, H., Tsutsumi, S., Tsukihara, H., Nakashima, Y., Ando, K., Imamura, Y., Ohgaki, K., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5376-z · Cited by 62
Tumour immunotherapy — leukocytes take up the fight
Alderton, G. K., & Bordon, Y. (2012) · Nature reviews. Immunology · doi:10.1038/nri3197 · Cited by 57
Zhang, X., Lin, A., Zhang, J. ‐., Bao, W. ‐., Xu, D., Ruan, Y., & Yan, W. (2012) · International Journal of Cancer · doi:10.1002/ijc.27621 · Cited by 55
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Mitri, D. D., Toso, A., & Alimonti, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2261 · Cited by 50
Hsia, J., Chen, J. T., Chen, C., Hsu, C. P., Miaw, J., Huang, Y. S., & Yang, C. (2005) · PubMed · Cited by 49
Zheng, J., Xu, C., Chu, D., Zhang, X., Li, J., Ji, G., Hong, L., Feng, Q., Li, X., Wu, G., et al. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.04.007 · Cited by 43
Wakita, A., Motoyama, S., Nanjo, H., Sato, Y., Yoshino, K., Sasaki, T., Kawakita, Y., Liu, J., Imai, K., Saito, H., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11467 · Cited by 40
Huang, H., Zhang, G., Li, G., Ma, H., & Zhang, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-3426-y · Cited by 39
Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
Jiao, R., Luo, H., Xu, W., & Ge, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214579 · Cited by 39
Albershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.10 · Cited by 38
Basis for molecular diagnostics and immunotherapy for esophageal cancer
Abdo, J., Agrawal, D. K., & Mittal, S. K. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1260449 · Cited by 35
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
Fujiwara, Y., Iguchi, H., Yamamoto, N., Hayama, M., Nii, M., Ueda, S., Komuro, K., Sugimoto, M., Vlahovic, G., & Kozuki, T. (2019) · Cancer Science · doi:10.1111/cas.14003 · Cited by 28
Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies
de Mello, R. A., Lordick, F., Muro, K., & Janjigian, Y. Y. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_236699 · Cited by 24
Nishimura, J., Tanaka, H., Yamakoshi, Y., Hiramatsu, S., Tamura, T., Toyokawa, T., Muguruma, K., Maeda, K., Hirakawa, K., & Ohira, M. (2019) · Esophagus · doi:10.1007/s10388-019-00669-w · Cited by 23
Baba, Y., Yagi, T., Kosumi, K., Okadome, K., Nomoto, D., Eto, K., Hiyoshi, Y., Nagai, Y., Ishimoto, T., Iwatsuki, M., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11301 · Cited by 19
Self-citationLim, K., Mimura, K., Kua, L., Shiraishi, K., & Kono, K. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000227 · Cited by 18
Metadata
- Authors
- Baba, Y., Nomoto, D., Okadome, K., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., & Baba, H.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2020-07-14
- Volume
- 111
- Issue
- 9
- Pages
- 3132-3141
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W3037477427
- Cited by
- 279
- References
- 69
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.